Form 4: Lynx1 Capital Management Increases Stake in TScan Therapeutics

Lynx1 Capital Management LP has increased its holdings in TScan Therapeutics through multiple purchases of common stock.

Summary

• Lynx1 Capital Management LP, a significant shareholder in TScan Therapeutics, has reported purchasing additional shares of common stock.
• On December 12, 2024, they acquired 31,800 shares at a weighted average price of $3.0072 per share.
• Following this, on December 13, 2024, they purchased another 100,000 shares at a weighted average price of $2.9014 per share.
• These transactions increased their total holdings to 5,357,347 shares.
• The purchases were made indirectly through Lynx1 Master Fund LP, with Lynx1 Capital Management LP acting as the investment manager.

Sentiment

Score: 7

Explanation: The document indicates a positive sentiment as a major shareholder is increasing their stake, suggesting confidence in the company. However, it is a routine filing and does not provide any new information about the company's performance.

Positives

• Lynx1 Capital Management's increased investment suggests confidence in TScan Therapeutics.
• The purchases demonstrate a commitment from a major shareholder.

Risks

• The document does not provide any information about the future performance of TScan Therapeutics.
• The document does not provide any information about the reasons for the purchases.

Industry Context

This filing is a routine disclosure of changes in beneficial ownership by a major shareholder, which is common in the biotech industry. It indicates continued interest in TScan Therapeutics by Lynx1 Capital Management.

Comparison to Industry Standards

• Similar filings are common for institutional investors in publicly traded companies, especially in the biotech sector where large ownership stakes are often held by investment funds.
• The reported transactions are typical for a fund adjusting its portfolio and are not unusual in the context of the broader market.

Stakeholder Impact

• The increased stake by Lynx1 Capital Management could be viewed positively by other shareholders, potentially increasing confidence in the company.
• The purchases may have a minor positive impact on the share price.

Key Dates

Keywords

TScan Therapeutics, Lynx1 Capital Management, Share Purchase, Beneficial Ownership, Stock Acquisition, TCRX